Zusammenfassung
Seit der Entdeckung und Strukturaufklärung von Prostaglandin (PG) E1 durch Bergström [1] und die bald darauffolgende klinische Erstanwendung durch Carlson und Mitarbeiter [2, 3] stand der Einfluß der Substanz auf die Plättchenfunktion im Zentrum der pathophysiologischen und therapeutischen Überlegungen. Erst die umfangreichere klinische Anwendung bei Patienten mit peripherer arterieller Verschlußkrankheit sowie Bemühungen der letzten Jahre, die Therapieform zu optimieren und Näheres über den Wirkungsmechanismus zu erfahren, führten zu einer wesentlichen Erweiterung des Wissenstandes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bergström S, Ryhage R, Samuelsson B, Sjövall J (1963) Prostaglandins and related factors. The structures of Prostaglandin and E1 F1α and F1β. J Biol Chem 238: 2355–3564
Carlson LA, Eriksson G (1973) Femoral artery infusion of Prostaglandin E1 in severe peripheral vascular disease. Lancet i: 155–156
Carlson LA, Irion E, Orö L (1968) Effect of infusion of Prostaglandin E1 on the aggregation of blood platelets in man. Life Sci 7: 85–89
Crutchley DJ, Cananan LB, Maynard JR (1982) Stimulation of fibrinolytic activity in human skin fibroblasts by Prostaglandins E1, E2 and I2. J Pharmacol Exp Ther 222: 544–549
Emmons PR, Hampton JR, Harrison MJG, Honour AJ, Mitchell JRA (1967) Effect of Prostaglandin E1 on platelet behaviour in vitro and in vivo. Brit Med J 2: 468–472
Feigl W, Sinzinger H, Wagner O, Leithner C (1975) Quantitative morphologic investigations on smooth muscle cells in vascular surgical specimens and their clinical importance. Experientia 31: 1352–1353
Gerber GV, Gerber G, Altman KI (1969) Studies on the metabolism of tissue proteins. I. Turnover of collagen labeled with proline 14 C in young rats. J Biol Chem 235: 2653–2657
Hecker G, König E, Ney P, Schrör K (1987) Potent inhibition of PAF-stimulated human platelets and polymorphonuclear leucocytes by the PGE1 analog OP-1206. In: Prostaglandins in Clinical Research, Eds. H. Sinzinger, K. Schrör (Hrsg), Alan Liss Inc, NY, 242, pp 317–322
Kinlough-Rathbone RL, Packham MA, Mustard JF (1970) The effect of Prostaglandin E1 on platelet function in vitro and in vivo. Brit J Haematol 19: 559–571
Klein K, Stachelberger H, Sinzinger H, Silberbauer K, Leithner C (1980) Effect of proteoglycans (Pg) and glycosaminoglycans (GAG) on prostacyclin (PGE1) and PGE1-formation of rat arteries. Artery 8: 37–42
Krone W, Klass A, Nägele H, Behnke B, Greten H (1986) Effects of Prostaglandin E1 on low-density lipoprotein receptor activity and cholesterol synthesis in freshly isolated human mononuclear leucocytes. In: Prostaglandin in Atherosclerosis, H. Sinzinger, W. Rogatti (Hrsg), Springer-Verlag, Berlin-Heidelberg-New York, pp 32–38
Kury PG, Ramwell PW, McConnel HM (1974) The effect of Prostaglandin E1 and E2 on the human erythrocyte as monitored by spin labels. Biochem Biophys Res Comm 56: 478–483
Rudofsky G (1986) Zur Wirkung von PGE1 am Ischämiemodell. Klin Wochenschrift 64 (Suppl): 257
Rudofsky G (1986) The effect of intra-arteriell and intravenous PGE1 in a model of ischaemia in healthy volunteers. In: Prostaglandin Et in Atherosclerosis, H. Sinzinger, W. Rogatti (Hrsg), Springer-Verlag, Berlin-Heidelberg-New York, pp 49–53
Simmet T, Fitscha P, Peskar BA, Sinzinger H, Rogatti W (1987) Studies on pharmacokinetics, platelet function and fibrinolytic activity under various Prostaglandin Ej infusion regimens. In: Prostaglandins in Clinical Research. Eds. H. Sinzinger, K. Schrör (Hrsg), Alan Liss Inc., New York, 264, pp 365–373
Sinzinger H, Fitscha P (1984) Scintigraphic detection of femoral atherosclerosis with 111-indium-labelled autologous platelets. VASA 13: 350–353
Sinzinger H, Fitscha P, Wagner O, Kaliman J, Rogatti W (1986) Prostaglandin Et decreases activation of arterial smooth muscle cells. Lancet i: 156–157
Sinzinger H (1986) Inhibition of mitotic and proliferative activity of smooth muscle cells by Prostaglandin E. In: Prostaglandin Ej in Atherosclerosis. H. Sinzinger, W. Rogatti (Hrsg), Springer-Verlag, Berlin-Heidelberg-New York, pp 39–48
Sinzinger H, Fitscha P, Zidek T, Firbas W (1987) Beneficial effect of Prostaglandin Ej on smooth muscle cell proliferation. In: Prostaglandins in Clinical Research. H. Sinzinger, K. Schrör (Hrsg), Alan R. Liss Inc., Philadelphia-New York, 242, pp 351–355
Sinzinger H, Fitscha P (1987) Influence of PGE1 on in-vivo accumulation of radiolabelled platelets and LDL on human arteries. VASA 17: 5–10
Sinzinger H, Zidek T, Rogatti W (1988) PGE1 reduces collagen and glycosaminoglycan synthesis in rabbit aorta. Exper Path (im Druck)
Smith DL, Willis AL, Mahmud I (1984) Eicosanoid effects on cell proliferation in vitro: relevance to atherosclerosis. Prostagl Leucotr Med 16: 1–10
Stary MC, McMillan GG (1983) Kinetics of cell proliferation in experimental atherosclerosis. Arch Pathol 89: 173–178
Weeks JR, Chandra Sekhar N, Ducharme DW (1981) Relative activity of Prostaglandin E1 A1, E2 and A2 on lipolysis, platelet aggregation, smooth muscle and cardiovascular system. J Pharm Pharmac 21: 103–108
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Sinzinger, H., Virgolini, I., Fitscha, P. (1988). Wirkungsmechanismen von Prostaglandin E1 bei Atherosklerose. In: Heidrich, H., Böhme, H., Rogatti, W. (eds) Prostaglandin E1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73943-9_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-73943-9_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73944-6
Online ISBN: 978-3-642-73943-9
eBook Packages: Springer Book Archive